Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Trading Down 1.5 %

PULM opened at $2.03 on Monday. The business’s 50 day moving average is $2.10 and its 200-day moving average is $1.98. The stock has a market cap of $7.41 million, a PE ratio of -0.84 and a beta of 0.99. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $2.75.

Pulmatrix (NASDAQ:PULM) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The business had revenue of $1.55 million for the quarter.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.